Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the FDA approval of rusfertide, a first-in-class hepcidin mimetic, for the treatment of erythrocytosis in adults with polycythemia vera (PV), based on the Phase II REVIVE (NCT04057040) and Phase III VERIFY (NCT05210790) trials. Dr Masarova explains that rusfertide added to standard of care showed superior hematocrit control and improved markers of iron deficiency; however, longer-term follow-up data are needed to understand its long-term clinical benefit and impact on inflammation. She notes that it may currently best benefit patients on cytoreductive therapy as an adjunct therapy, as well as those with significant iron deficiency symptoms. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.